QPPV.COM KNOWLEDGE ASSESSMENT

Amlodipine: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Amlodipine: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient develops dizziness several days after an amlodipine dose increase. Which pharmacokinetic feature is most relevant when interpreting the timing?
Question 2 of 10 An older patient with hepatic impairment develops hypotension after an amlodipine dose increase. Which interpretation is most appropriate?
Question 3 of 10 What did PRAISE-2 contribute to understanding amlodipine use in severe non-ischaemic heart failure?
Question 4 of 10 An adverse pregnancy outcome is reported following maternal amlodipine exposure. Which approach best avoids an unsupported causal conclusion?
Question 5 of 10 Which statement correctly distinguishes the discovery and patent period from the initial US approval?
Question 6 of 10 Which statement best distinguishes minimum ICSR validity from the information needed for a strong medical assessment?
Question 7 of 10 A dispensing error leads to an unintended extra amlodipine dose, but no harm is reported. Which statement is most appropriate?
Question 8 of 10 Which evidence would best demonstrate a functioning pharmacovigilance process during an inspection of an oedema case later followed by a heart-failure diagnosis?
Question 9 of 10 A patient taking amlodipine reports new bilateral ankle swelling. What is the most appropriate initial pharmacovigilance interpretation?
Question 10 of 10 A patient with severe aortic stenosis reports presyncope after starting amlodipine. Which consideration is specifically relevant to the safety assessment?

Select an answer to continue.

QPPV.com